Drug Profile
Kallikrein gene therapy
Latest Information Update: 30 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antihypertensives; Gene therapies
- Mechanism of Action Kallikrein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension; Ischaemic heart disorders